Glucosamine may speed the path to dementia
Millions of people take glucosamine daily to ease joint pain. A large new study suggests the supplement may speed the transition to dementia. The finding is unexpected and raises urgent questions.
Glucosamine is one of the world’s best-selling supplements. It is typically taken to support cartilage and reduce joint discomfort. Few users or physicians had reason to think it might affect the brain.
The researchers found that people with mild cognitive impairment (MCI), an early stage of memory decline, who used glucosamine had a 25 percent higher likelihood of progressing to Alzheimer’s disease. The study also identified biological clues that could help explain the association. This is a preliminary finding, not a proven causal relationship.
What is mild cognitive impairment?
Mild cognitive impairment, or MCI, sits between normal aging and dementia. A person with MCI notices memory problems but can still function independently. Not everyone with MCI develops Alzheimer’s, but the risk is elevated. The study focused specifically on this higher-risk group.
Biological clues, but no firm mechanism yet
The researchers report biological indicators that could help explain the association. The source text does not fully detail which molecular mechanisms are involved, making this a preliminary result that requires further investigation. From a longevity perspective, that matters: supplements in widespread use without long-term brain health data deserve closer scrutiny.
People taking glucosamine need not stop based on a single study. But the finding is significant enough to discuss with a physician, especially for anyone already experiencing cognitive changes. Follow-up research will need to confirm whether the association holds and clarify the underlying biology.